Table 3 Changes in tumor volume and SUVmax in NEOSTAR patients with abnormal nodes post-therapy.

From: Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer

NEOSTAR cohort

Tumor volume (mL)

NIF (n = 7)

  

No-NIF (n = 18)

  

NIF (n = 7)

No-NIF (n = 18)

 

Pre-ICIs

Post-ICIs

 

Pre-ICIs

Post-ICIs

 

Change (Post–Pre)

Change (Post–Pre)

 

Mean (SD)

Mean (SD)

P value

Mean (SD)

Mean (SD)

P value

Mean (SE)

Mean (SE)

P value

23.8 (8.60)

17.1 (13.7)

0.496

49.0 (50.9)

37.1 (44.5)

0.059

−6.67 (9.65)

−12.0 (6.02)

0.089

Tumor SUVmax

NIF (n = 7)

  

No-NIF (n = 17)^

  

NIF (n = 7)

No-NIF (n = 17)^

 

Pre-ICIs

Post-ICIs

 

Pre-ICIs

Post-ICIs

 

Change (Post–Pre)

Change (Post–Pre)

 

Mean (SD)

Mean (SD)

P value

Mean (SD)

Mean (SD)

P value

Mean (SE)

Mean (SE)

P value

10.4 (4.40)

8.98 (6.56)

0.643

14.4 (6.93)

14.7 (9.05)

0.867

−1.39 (2.95)

0.32 (1.89)

0.142

  1. n, Number of patients. NIF nodal immune flare, SD standard deviation, SE standard error. ^One patient did not have post-ICI PET/CT images. SUVmax, maximum standardized uptake value. Two-sided P value is from linear mixed-effects model for tumor size and tumor SUVmax comparisons. Source data are provided as a Source Data file.
Back to article page